Keros Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 561.7K | $6.20M | 0.00% | Trimmed-47.8% | 2026-03-31 |
| DEShaw | quant | 509.6K | $5.63M | 0.00% | Trimmed-32.5% | 2026-03-31 |
| RenTech | quant | 453.5K | $5.01M | 0.01% | Trimmed-23.4% | 2026-03-31 |
| TwoSigma | quant | 363.8K | $4.02M | 0.00% | Added+14.3% | 2026-03-31 |
| Citadel | multi-strat | 109.0K | $1.20M | 0.00% | Added+180.6% | 2026-03-31 |
| FidelityFMR | fundamental | 32.7K | $360.72K | 0.00% | Trimmed-8.2% | 2026-03-31 |
| TRowePrice | fundamental | 45.9K | $507 | 0.00% | Added+54.5% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | -1.25 | — | — |
| 2026-05-14 | -0.92 | -1.21 | -31.52% |
| 2026-03-04 | -0.45 | -0.86 | -90.40% |
| 2025-11-05 | -0.92 | -0.18 | +80.46% |
| 2025-08-06 | -1.13 | -0.76 | +32.54% |
| 2025-05-06 | 0.01 | 3.62 | +48166.67% |
| 2025-02-26 | -0.43 | -1.14 | -166.98% |
| 2024-11-06 | -1.28 | -1.41 | -10.52% |
| 2024-08-07 | -1.25 | -1.25 | +0.20% |
| 2024-05-08 | -1.33 | -1.21 | +9.28% |
| 2024-02-28 | -1.39 | -1.34 | +3.68% |
| 2023-11-06 | -1.35 | -1.33 | +1.38% |
| 2023-08-07 | -1.35 | -1.27 | +6.12% |
| 2023-05-04 | -1.14 | -1.26 | -10.33% |
| 2023-03-03 | -1.10 | -1.09 | +1.27% |
| 2022-11-03 | -1.26 | -0.92 | +26.98% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| KROS | -2.09% | -16.04% | -44.74% | -20.49% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -5.06% | -11.41% | -41.30% | -33.18% |